Vanda Bets Big on Solving GLP-1’s Biggest Problem: Vomiting

GLP-1 drugs are winning. Patient adherence is not. That gap is where Vanda Pharmaceuticals is placing its next bet.

The company has launched a new clinical trial, Thetis—to test whether its drug, Nereus (tradipitant), can prevent vomiting in patients using GLP-1 therapies.

If it works, this could unlock the full potential of blockbuster drugs like semaglutide and tirzepatide.

The GLP-1 Boom Has a Dirty Secret

GLP-1 receptor agonists have reshaped treatment for:

• Type 2 diabetes
• Obesity

They deliver meaningful weight loss. They improve metabolic health. They dominate headlines. But there’s a catch.

The Side Effects Problem

The most common reasons patients stop treatment:

• Nausea
• Vomiting

These aren’t minor inconveniences. They directly impact:

• Treatment adherence
• Dose escalation
• Long-term outcomes

Even newer, higher-dose versions amplify the issue. Take Wegovy as an example.

• Higher doses deliver better weight loss
• But they also increase nausea and vomiting rates

This creates a tradeoff: efficacy vs tolerability

Vanda’s Strategy: Fix the Bottleneck

Instead of competing with GLP-1 drugs, Vanda is building alongside them. Their hypothesis is simple:

If you reduce side effects, you increase adherence—and unlock full therapeutic value. Enter Nereus (tradipitant).

What is Tradipitant?

• A neurokinin-1 (NK1) receptor antagonist
• Already approved for motion-induced vomiting
• Licensed from Eli Lilly and Company

Its role here is clear: block the vomiting pathway triggered by GLP-1 drugs

The Thetis Study: Designed for Real-World Pain Points

The Thetis trial is structured to answer one question: Can tradipitant prevent vomiting in patients starting high-dose GLP-1 therapy?

Trial Design

• Multicenter
• Randomized
• Double-blind
• Placebo-controlled

Key Endpoint

• Percentage of patients with zero vomiting episodes

Patient Focus

• Individuals starting high-dose GLP-1 treatment immediately
• This mirrors real-world pressure to accelerate weight-loss outcomes

Topline results are expected in Q4 2026.

Phase 2 Data: Early Signal Looks Strong

Vanda isn’t starting from scratch. A prior Phase 2 study tested a similar setup using high-dose Wegovy.

Results That Matter

• Vomiting incidence
  • Tradipitant: 29.3%
  • Placebo: 58.6%
  • → ~50% relative reduction
• Vomiting + significant nausea
  • Tradipitant: 22.4%
  • Placebo: 48.3%

Both endpoints were statistically significant.

Translation

• Fewer patients got sick
• More patients tolerated aggressive dosing
• Better odds of staying on therapy

That’s a strong signal heading into Thetis.

Why This Matters More Than It Seems?

This isn’t just about symptom control. It’s about expanding the ceiling of GLP-1 therapies.

If Tradipitant Works at Scale:

• Patients can start at higher doses
• Fewer dropouts
• Faster clinical outcomes
• Better real-world effectiveness

In short: same drugs, better results

What Comes Next?

Even if Thetis succeeds, approval isn’t immediate. Vanda has already indicated:

• Additional studies may be required
• A New Drug Application (NDA) will follow later

But the direction is clear.

The Bigger Trend: Companion Drugs for Blockbusters

This move reflects a larger shift in pharma strategy:

Instead of building competing therapies, companies are:

• Enhancing existing winners
• Solving their limitations
• Extending lifecycle value

Tradipitant could become a companion drug to GLP-1 therapies. And that’s a massive market.

Final Take

GLP-1 drugs changed the game. But side effects are still holding them back. Vanda isn’t trying to replace the winners. They’re trying to make them work better. If Thetis delivers, tradipitant could quietly become one of the most important add-ons in metabolic medicine.